MDT

96.53

+0.95%↑

VEEV

287.9

+0.6%↑

A

138.07

-0.18%↓

HQY

93.65

+0.53%↑

PHR.US

22.97

+3.56%↑

MDT

96.53

+0.95%↑

VEEV

287.9

+0.6%↑

A

138.07

-0.18%↓

HQY

93.65

+0.53%↑

PHR.US

22.97

+3.56%↑

MDT

96.53

+0.95%↑

VEEV

287.9

+0.6%↑

A

138.07

-0.18%↓

HQY

93.65

+0.53%↑

PHR.US

22.97

+3.56%↑

MDT

96.53

+0.95%↑

VEEV

287.9

+0.6%↑

A

138.07

-0.18%↓

HQY

93.65

+0.53%↑

PHR.US

22.97

+3.56%↑

MDT

96.53

+0.95%↑

VEEV

287.9

+0.6%↑

A

138.07

-0.18%↓

HQY

93.65

+0.53%↑

PHR.US

22.97

+3.56%↑

Search

Day One Biopharmaceuticals Inc

Fermé

SecteurSoins de santé

7.07 -1.39

Résumé

Variation du prix de l'action

24h

Actuel

Min

7

Max

7.16

Chiffres clés

By Trading Economics

Revenu

5.7M

-30M

Ventes

3.1M

34M

Marge bénéficiaire

-89.424

Employés

182

EBITDA

5.2M

-35M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+223.37% upside

Dividendes

By Dow Jones

Prochains Résultats

29 oct. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

65M

748M

Ouverture précédente

8.46

Clôture précédente

7.07

Sentiment de l'Actualité

By Acuity

50%

50%

166 / 371 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Day One Biopharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

14 oct. 2025, 22:33 UTC

Résultats

America Movil 3Q Profit Jumps on Higher Revenue, Lower Financial Costs

14 oct. 2025, 22:21 UTC

Principaux Mouvements du Marché

Dentsply Sirona Shares Rise After SEC Probe Ends

14 oct. 2025, 19:27 UTC

Acquisitions, Fusions, Rachats

Bouygues Telecom, Free-iliad, Orange Offer to Buy Most Altice French Assets for About $20 Billion

14 oct. 2025, 17:56 UTC

Principaux Mouvements du Marché

Nova Minerals Surges; Will Provide Minerals Briefing to Australian Government Ahead of Trump Meeting

14 oct. 2025, 23:38 UTC

Market Talk

Nikkei May Rise Amid Possible Bargain-Hunting -- Market Talk

14 oct. 2025, 22:12 UTC

Market Talk
Résultats

Fletcher Building's 1H Earnings Likely Down 16% -- Market Talk

14 oct. 2025, 21:40 UTC

Résultats

America Movil 3Q EBITDA MXN93.82B, Up 4.9% on Year >AMX.MX

14 oct. 2025, 21:39 UTC

Résultats

America Movil 3Q Rev MXN232.92B, Up 4.2% on Year >AMX.MX

14 oct. 2025, 21:38 UTC

Résultats

America Movil 3Q Net MXN22.7B Vs. Net MXN6.43B Year Ago >AMX.MX

14 oct. 2025, 21:06 UTC

Résultats

These Stocks Moved the Most Today: JPMorgan, Wells Fargo, Goldman, AMD, Walmart, J&J, Navitas, Polaris, and More -- Barrons.com

14 oct. 2025, 20:50 UTC

Market Talk
Résultats

Financial Services Roundup: Market Talk

14 oct. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

14 oct. 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

14 oct. 2025, 20:50 UTC

Market Talk
Résultats

Health Care Roundup: Market Talk

14 oct. 2025, 20:13 UTC

Résultats

BlackRock's Assets Hit Record $13.5 Trillion After Market Rally, Dealmaking Spree -- 2nd Update

14 oct. 2025, 20:01 UTC

Résultats

Goldman Sachs Profit Surges, Fueled by Dealmaking Boom -- 5th Update

14 oct. 2025, 19:21 UTC

Market Talk
Résultats

Citigroup's Higher Outlook Leaves Questions -- Market Talk

14 oct. 2025, 19:12 UTC

Acquisitions, Fusions, Rachats

Bouygues Telecom, Free-iliad, Orange Offer to Buy Most Altice French Assets for About $20B

14 oct. 2025, 19:08 UTC

Market Talk

Oil Futures Settle Lower on Trade, Oversupply Concerns -- Market Talk

14 oct. 2025, 19:02 UTC

Market Talk

U.S. Natural Gas Falls as Weather Outlook Stays Mild -- Market Talk

14 oct. 2025, 18:59 UTC

Acquisitions, Fusions, Rachats

Bouygues Telecom, Free-iliad Group, Orange Bid for Corresponds to Total Enterprise Value of EUR17B for Altice France Assets

14 oct. 2025, 18:58 UTC

Acquisitions, Fusions, Rachats

Bouygues Telecom, Free-iliad Group, Orange Bid Excludes Stakes in Intelcia, UltraEdge, XP Fibre, Altice Technical Services

14 oct. 2025, 18:58 UTC

Acquisitions, Fusions, Rachats

Bouygues Telecom, Free-iliad Group, Orange Bid Covers Most SFR Assets

14 oct. 2025, 18:56 UTC

Acquisitions, Fusions, Rachats

Bouygues Telecom, Free-iliad Group, Orange Submit Joint Non-Binding Offer to Buy Large Part of Altice's Activities in France

14 oct. 2025, 18:46 UTC

Résultats

These Stocks Are Moving the Most Today: JPMorgan, Wells Fargo, Goldman, AMD, Walmart, J&J, Navitas, Polaris, and More -- Barrons.com

14 oct. 2025, 18:04 UTC

Résultats

Goldman Sachs Profit Surges, Fueled by Dealmaking Boom -- 4th Update

14 oct. 2025, 18:01 UTC

Market Talk

Gold Finds Another Record as Traders Eye Further Upside -- Market Talk

14 oct. 2025, 17:54 UTC

Résultats

Salesforce's Dreamforce Conference Kicks Off. CEO Benioff Touts AI Tool Agentforce. -- Barrons.com

14 oct. 2025, 17:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14 oct. 2025, 17:50 UTC

Market Talk

Lower Dollar Provides Some Strength in Grains -- Market Talk

Comparaison

Variation de prix

Day One Biopharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

223.37% hausse

Prévisions sur 12 Mois

Moyen 23.25 USD  223.37%

Haut 34 USD

Bas 16 USD

Basé sur 10 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

10 ratings

9

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

6.26 / 7.47Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

166 / 371Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Moyen

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
help-icon Live chat